Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

Given the new guidelines, price reductions, and the reduction in associated all-cause mortality reported with alirocumab in ODYSSEY Outcomes, which patients should now be embraced as plausible candidates for PCSK9-mediated CV risk reduction?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Michael Blaha, MD, MPH

Michael Blaha, MD, MPH

Director of Clinical ResearchCiccarone Center for the Prevention of Heart DiseaseAssociate Professor of MedicineJohns Hopkins School of MedicineBaltimore, MD